Compare SCM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | ACIU |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 247.6M |
| IPO Year | 2012 | 2015 |
| Metric | SCM | ACIU |
|---|---|---|
| Price | $8.74 | $2.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | 174.1K | ★ 223.6K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.33 | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $14.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.83 | $2.04 |
| 52 Week High | $14.85 | $4.00 |
| Indicator | SCM | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 57.07 |
| Support Level | $8.43 | $2.57 |
| Resistance Level | $8.97 | $3.13 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 48.94 | 55.46 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.